BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
'A completely new manufacturing frontier': Space Forge fires up 1st commercial semiconductor factory in space - 2'No Kings' protests live updates: More than 8 million turned out across all 50 states, organizers say
- 3Cyber Monday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- 4Brazil's Bolsonaro to continue his sentence at home because of poor health
- 5Find Exemplary Scents: An Extensive Aide
- Illustrations Gained from a Crosscountry Excursion
- Oldest sequenced RNA reveals details about a mammoth’s final moments 40,000 years
- New images reveal interstellar comet 3I/ATLAS approaching Earth
- Benin coup thwarted by loyalist troops, president tells nation
- Landslides triggered by heavy rainfall kill at least 20 people in Tanzania
- Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment
- Getting through a Lifelong Change: Individual Examples of overcoming adversity
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- Over 60 local leaders push Netanyahu to halt haredi draft bill, warn of social rift
